This company has been marked as potentially delisted and may not be actively trading. Lionheart Acquisition Co. II (LCAP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock LCAP vs. OCUL, LQDA, ADUS, ARDT, CERT, APGE, CELC, DYN, ATEC, and TWSTShould you be buying Lionheart Acquisition Co. II stock or one of its competitors? The main competitors of Lionheart Acquisition Co. II include Ocular Therapeutix (OCUL), Liquidia Technologies (LQDA), Addus HomeCare (ADUS), Ardent Health (ARDT), Certara (CERT), Apogee Therapeutics (APGE), Celcuity (CELC), Dyne Therapeutics (DYN), Alphatec (ATEC), and Twist Bioscience (TWST). These companies are all part of the "medical" sector. Lionheart Acquisition Co. II vs. Its Competitors Ocular Therapeutix Liquidia Technologies Addus HomeCare Ardent Health Certara Apogee Therapeutics Celcuity Dyne Therapeutics Alphatec Twist Bioscience Ocular Therapeutix (NASDAQ:OCUL) and Lionheart Acquisition Co. II (NASDAQ:LCAP) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Is OCUL or LCAP more profitable? Lionheart Acquisition Co. II has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -382.51%. Lionheart Acquisition Co. II's return on equity of -44.30% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-382.51% -71.92% -49.36% Lionheart Acquisition Co. II N/A -44.30%1.39% Do institutionals and insiders have more ownership in OCUL or LCAP? 59.2% of Ocular Therapeutix shares are held by institutional investors. 2.3% of Ocular Therapeutix shares are held by company insiders. Comparatively, 19.4% of Lionheart Acquisition Co. II shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer OCUL or LCAP? In the previous week, Ocular Therapeutix had 20 more articles in the media than Lionheart Acquisition Co. II. MarketBeat recorded 20 mentions for Ocular Therapeutix and 0 mentions for Lionheart Acquisition Co. II. Ocular Therapeutix's average media sentiment score of 0.59 beat Lionheart Acquisition Co. II's score of 0.00 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Overall Sentiment Ocular Therapeutix Positive Lionheart Acquisition Co. II Neutral Do analysts rate OCUL or LCAP? Ocular Therapeutix currently has a consensus target price of $22.63, suggesting a potential upside of 90.93%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, equities research analysts plainly believe Ocular Therapeutix is more favorable than Lionheart Acquisition Co. II.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75Lionheart Acquisition Co. II 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings & valuation, OCUL or LCAP? Lionheart Acquisition Co. II has lower revenue, but higher earnings than Ocular Therapeutix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$63.72M32.36-$193.51M-$1.28-9.26Lionheart Acquisition Co. IIN/AN/A$3.21MN/AN/A Which has more risk & volatility, OCUL or LCAP? Ocular Therapeutix has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, Lionheart Acquisition Co. II has a beta of 0.08, meaning that its stock price is 92% less volatile than the S&P 500. SummaryOcular Therapeutix beats Lionheart Acquisition Co. II on 8 of the 13 factors compared between the two stocks. Get Lionheart Acquisition Co. II News Delivered to You Automatically Sign up to receive the latest news and ratings for LCAP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LCAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LCAP vs. The Competition Export to ExcelMetricLionheart Acquisition Co. IIBusiness Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$527.58M$154.58M$6.05B$10.30BDividend YieldN/AN/A5.73%4.82%P/E RatioN/A338.6485.3127.10Price / SalesN/A13.51601.46133.29Price / Cash20.6411.7025.7730.18Price / Book-10.032.8012.676.69Net Income$3.21M$1.30M$3.32B$276.55M Lionheart Acquisition Co. II Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LCAPLionheart Acquisition Co. IIN/A$28.59-2.4%N/A+19,864.2%$527.58MN/A0.003OCULOcular Therapeutix3.9091 of 5 stars$12.32+6.9%$22.63+83.7%+20.4%$2.14B$63.72M-9.62230Insider TradeAnalyst RevisionLQDALiquidia Technologies3.3629 of 5 stars$24.53+2.1%$32.38+32.0%+109.5%$2.11B$14M-14.4350ADUSAddus HomeCare4.9462 of 5 stars$113.74+2.8%$138.89+22.1%-13.6%$2.10B$1.15B25.1149,703ARDTArdent Health3.8288 of 5 stars$14.65+0.2%$19.33+32.0%-25.8%$2.10B$5.97B8.0924,900Positive NewsCERTCertara4.5419 of 5 stars$13.02+0.7%$15.63+20.0%+3.6%$2.09B$385.15M260.451,546Analyst RevisionAPGEApogee Therapeutics3.0683 of 5 stars$45.32+14.1%$92.63+104.4%-7.9%$2.09BN/A-10.9791CELCCelcuity2.3678 of 5 stars$48.80-0.8%$56.50+15.8%+203.9%$2.07BN/A-14.1240DYNDyne Therapeutics3.5583 of 5 stars$14.37+3.0%$34.07+137.1%-58.3%$2.04BN/A-3.72100Analyst DowngradeATECAlphatec4.3666 of 5 stars$13.68+1.7%$18.50+35.3%+155.1%$2.02B$611.56M-12.08700Positive NewsTWSTTwist Bioscience3.7771 of 5 stars$33.13+6.5%$48.50+46.4%-29.9%$2.00B$312.97M-22.86990 Related Companies and Tools Related Companies OCUL Alternatives LQDA Alternatives ADUS Alternatives ARDT Alternatives CERT Alternatives APGE Alternatives CELC Alternatives DYN Alternatives ATEC Alternatives TWST Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LCAP) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lionheart Acquisition Co. II Please log in to your account or sign up in order to add this asset to your watchlist. Share Lionheart Acquisition Co. II With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
